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with low-risk myocardial infarction. METHODS: The partici-
pants in this 12-month prospective study were 153 consecutive
patients with low-risk myocardial infarction (MI) referred to
their primary care center for follow-up care. Of these patients,
113 were referred to a mixed primary and specialized care
program that included physical exercise, cardiovascular risk
control, an antismoking program, health education talks and
psychological evaluation. The other 40 patients served as con-
trols. We analyzed the results after three months and 1 year of
follow-up. RESULTS: There were no differences between the two
groups at baseline. After 1 year, improvements were seen in
smoking habit (4.6% vs. 15.6%; P < 0.05) and body mass index
(26 [2] vs. 29 [2]; P < 0.05). Dyslipidemia, glucose and blood
pressure were similar in both groups after follow-up. Greater
improvements in the group of patients who participated in the
program were seen after 1 year in quality of life (78 [2] vs. 91
[2]; P < 0.05), exercise capacity (10.3 [2] vs. 8.4 [3]; P < < 0.01)
and return to active employment (84.6% vs. 53.3%; P < 0.05).
CONCLUSIONS: After one year of follow-up, the cardiac reha-
bilitation program coordinated by cardiological and primary
care services for low-risk post-MI patients improved quality of
life, and increased exercise tolerance, active employment, and the
number of participants who quit smoking. The mixed program
also reduced body mass index. These results suggest the need for
similar programs.
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OBJECTIVE: To estimate the direct medical costs in patients at
high risk that suffered an atherotrombotic event (AE), i.e., the
cost of the acute event and the costs related to the disease during
a two year follow up period in patients with myorcardial infarc-
tion and stroke, treated in third care level in private institutions
in the Mexican Health System. METHODS: This is a descrip-
tive observational and multicentric study. Each patient included
in the study cohort has an active medical ﬁle with a complete
record for at least a 2-year period after the AE. This study is
based on an incidence costing approach and only includes the
perspective of the payments. The unitary costs used are those
ofﬁcially published by private institutions. All the amounts are
set in 2005 Mexican pesos. The 2005 exchange rate is 11
Mexican pesos per US dollar. RESULTS: A patient who experi-
ences a stroke stays at least 5 days in Intensive Care. The
expected cost per treated patient with stroke reaches US$7876.
The most important category of cost during the acute phase is
hospitalization (US$3924; 50%). On the other hand, the total
direct cost incurred per patient with acute coronary syndrome
(ACS) is US$3367 per year of follow-up and US$16,381 in the
acute event. The most relevant costs are both pharmacy costs
(US$2354) and revascularization procedures (US$9319). Coro-
nary artery stent implantation is the most common revascular-
ization procedure (70%). CONCLUSIONS: AE are associated
with high costs during the years after the acute event, in special
high incidence of hospitalization and drug cost. These results,
especially the proportions between cost items, are consistent with
international studies. Effective prevention and treatment of AE
should be targeted not only on patients and medical profession-
als but also on health decision makers.
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OBJECTIVE: To estimate the long-term economic and health
impact of managing bradycardia due to sinoatrial node disease
or atrioventricular block with a dual (DDD or DDDR) vs. single
chamber ventricular pacemaker (VVI or VVIR). METHODS: A
discrete event simulation was constructed to evaluate the out-
comes over ﬁve years. During the simulation, each patient may
develop post-operative complications, severe pacemaker syn-
drome leading to replacement of the VVI(R) with DDD(R), atrial
ﬁbrillation (which may become chronic and require anticoagu-
lants), or have a stroke. A time for each event is sampled from
the distribution of failure times speciﬁed by the individual’s risk
proﬁle. Life expectancy was estimated and assumed the same
with either device. Model risk functions are based on long-term
randomized trials (Canadian Trial of Physiological Pacing and
Mode Selection Trial in Sinus-Node Dysfunction). Probabilistic
sensitivity analyses were performed for key input parameters.
Direct medical costs are reported in 2004 Euros (€). Beneﬁts and
costs are discounted at 3% per year. RESULTS: Chronic atrial
ﬁbrillation was estimated to be 24% lower with DDD(R). Dis-
counted costs over 5 years were about €10,000 per patient in
either cohort, mean net additional cost of €106 with DDD(R).
DDD(R) led to 0.09 additional QALY; a mean cost-effectiveness
ratio of €1177/QALY, with 21% of replications indicating dom-
inance for DDD(R). Severe pacemaker syndrome requiring
switch to DDD(R) occurred in 16.8% with VVI(R); the results
are sensitive to the proportion that would seek replacement.
CONCLUSION: Lower initial costs with VVI(R) were offset by
second operations to switch to DDD(R) and costs of atrial ﬁb-
rillation. Thus, dual chamber pacemakers are economically
attractive in management of patients with bradycardia.
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OBJECTIVES: To evaluate short-term cost-effectiveness (cost-
utility) of cilostazol for the treatment of intermittent claudica-
tion from the perspective of the Scottish NHS. METHODS: A
decision analytic model was constructed and analysed from the
perspective of the Scottish NHS. Costs include direct medical
costs including drug costs -evaluated at retail prices excluding
taxes, and treatment costs. Treatment costs included the cost of
primary and specialist care of intermittent claudication patients
based on an independent survey of expert clinical opinion in
Scotland. Short- term effectiveness was based on two published
24 week randomised clinically controlled trials of cilostazol 
(100mg) versus placebo. Placebo was chosen as the comparator
since the majority of patients in Scotland do not currently receive
intermittent claudication- speciﬁc medical treatment. Health-
related quality of life was measured in the trials using the SF-36;
these scores were translated into utilities using a validated
mapping algorithm. QALYs were estimated over various scenar-
ios including the base-case analysis of the most conservative
assumption of immediate return to placebo utility post treat-
ment. RESULTS: The incremental cost- utility ratio for cilosta-
zol over placebo was estimated at approximately £12,500 per
QALY. The data were not discounted due to the short time
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horizon of the trial. Sensitivity analysis suggested that the results
were most sensitive to the cost of an angiography, the utility
values estimated, and the price of cilostazol. CONCLUSIONS:
Cilostazol is expected to be a cost-effective treatment for inter-
mittent claudication patients in Scotland.
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OBJECTIVE: Reduced hospital stay and intensive care unit stay
after endovascular aneurysm repair (EVAR) compared to open
repair (OR) of abdominal aortic aneurysms (AAA) are expected
to result in reduced costs of AAA repair. The cost and cost effec-
tiveness of OR and EVAR in the ﬁrst postoperative year were
compared in a randomised trial. METHODS: In a multicenter
randomised trial comparing OR and EVAR we randomly
assigned 149 patients to OR and 151 to EVAR. Complications,
costs and cost-effectiveness were determined one year after
surgery. The uncertainty surrounding the cost-effectiveness ratios
(iCER) was addressed by bootstrapping. RESULTS: Ten patients
had died in the OR group and 9 in the EVAR group (chi-square
p = 0.8). In the OR group, 32 patients had one or more severe
complications and in the EVAR group, 27 patients (chi-square p
= 0.5). EVAR was associated with €4.480 additional direct costs
per patient (€18.138 versus €13.659) and a decrease in QALY 
of 0.72 as compared with 0.73 (difference 0.01 year, 95% CI 
-0.04–0.06). With regard to event free survival over 85% of the
bootstrap estimates EVAR indicated favourable health outcomes
for EVAR, but against prohibitively higher costs. From a health
economic perspective OR is preferred. CONCLUSION: In
patients suitable for both treatments, EVAR is not cost-effective
in the ﬁrst postoperative year.
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OBJECTIVES: Open Surgery (OS) of abdominal aortic
aneurysms (AAAs) is a major surgical procedure with elevated
morbidity and a low but deﬁnite mortality. Endovascular repair
(EVAR) has now emerged as a minimally alternative to OS, and
its effectiveness has now been reported in the literature with
reduced peri-operative mortality and complication rates. The
aim of this study was to compare the full cost of the two treat-
ments. METHODS: A prospective, observational study was con-
ducted in a Vascular-Surgery Division from October 2003 to
April 2004. Data for patients undergoing treatment of an AAA
were collected. Cost assessment was carried out from the hospi-
tal perspective according to the Activity Based Costing princi-
ples. RESULTS: Data for 44 patients were gathered: 73%
underwent OS and 27% EVAR. The mean age was 66.7 (±16.7)
years and 7% of the patients were female. Comorbidity rates
were similar in the two treatments group. There was no differ-
ence in mean hospital length of stay (LOS) between the two
options (ten days). Mean post-operative LOS was 6.5 days (±4),
with signiﬁcant difference between the two groups (OS 7.5 ± 4
vs. EVAR 3.5 ± 0.6, p < 0.0001). Intensive therapy was neces-
sary only for OS patients (28%). The study revealed that the
overall mean cost to treat an AAA, irrespective of the technique
used, was €11,578.34 (€11,063.31 OS vs. 12,971.56 EVAR). A
sub-analysis was performed for complicated patients alone and
the mean cost was €13,487.46, with a difference between the
two treatments tending almost to zero. The use of post-
operative resources differed between the two treatments, result-
ing in differences for the mean post-operative costs (€5,686.07
for OR vs. €2,185.49 for EVAR). CONCLUSIONS: Stent graft
treatment of AAAs has been shown to be effective in reducing
the amount of nursing assistance, LOS and the need for inten-
sive therapy at the post-operative stage.
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OBJECTIVES: Bypass surgeries to circumvent occluded arteries
are common procedures not only in cardiac surgery but also for
occlusions in lower extremities or thorax. Different materials for
the bypass procedures are available: venous, arterial and syn-
thetic; each with different properties, advantages and costs. The
objective is to assess and compare the effectiveness and beneﬁt
of various bypass materials in leg bypass surgery from a medical
and economic perspective. METHODS: A systematic review of
the literature was performed using established electronic data
bases including Medline, Embase, Cochrane Library and others
for literature from 1999–2004 in English and German. Of 4526
articles originally retrieved, 630 where examined in detail.
RESULTS: The systematic review of literature resulted in two
systematic reviews and eleven randomized trials comparing the
medical effects of different bypass materials in leg bypass surgery.
Primary patency (deﬁned as the presence of a patent graft
without any additional intervention) is the main outcome
measure from a medical perspective. From an economic per-
spective different bypass materials are evaluated insufﬁciently.
Therefore a model has been developed to determine cost-
effectiveness of different bypass materials including the cost of
the prosthetic material and operation time. For long-term results
complication rates have to be considered as well. CONCLU-
SIONS: From a medical perspective autologous material is the
superior choice compared to prosthetic materials in leg bypass
surgery. According to the developed model the cost-effectiveness
of different bypass materials depends on the costs and structure
of the hospital. The experience of the surgeon is an important
factor.
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OBJECTIVES: Technological advances have enabled percuta-
neous coronary intervention (PCI) to be applied to expanding
indications. However, escalating costs are of concern to patients,
providers and payers. This study assessed the incremental
medical costs of treating major in-hospital procedural complica-
tions incurred by patients undergoing PCI. METHODS: We con-
